We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STERIS Poised on Synergy Health Addition amid Currency Woes
Read MoreHide Full Article
On Sep 8, we issued an updated research report on OH-based STERIS plc (STE - Free Report) – a manufacturer and marketer of infection prevention, decontamination, microbial reduction, along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #3 (Hold).
On the bright side, Synergy Health – the company STERIS acquired last year − was one of the primary contributors to the strong double-digit revenue growth observed by the combined company. Management expects Synergy to contribute between $640–$650 million in fiscal 2017 which translates into low-single-digit sales growth.
STERIS has always been on track with its strategy of acquisitions for growth. In Jul 2016, the company bought Medisafe Holdings, which is a U.K.-based manufacturer of washer disinfector equipment and also markets related consumables and services. Per management, Medisafe’s products and services complement STERIS’ global healthcare offering by providing washer R&D and production in the U.K.
However, currency has been a major obstacle to STERIS' growth for quite some time. During first-quarter fiscal 2017, currency fluctuations affected STERIS’ revenues by 40 basis points. Additionally, the company’s lowered revenue guidance for fiscal 2017 was disappointing.
Moreover, the current macroeconomic turmoil in countries of the Middle East, owing to fluctuating oil prices, affected STERIS’ top line in the first quarter. Similar macroeconomic challenges were also witnessed across Latin America, Venezuela and Brazil.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STERIS Poised on Synergy Health Addition amid Currency Woes
On Sep 8, we issued an updated research report on OH-based STERIS plc (STE - Free Report) – a manufacturer and marketer of infection prevention, decontamination, microbial reduction, along with surgical and gastrointestinal support products and services. The company currently carries a Zacks Rank #3 (Hold).
On the bright side, Synergy Health – the company STERIS acquired last year − was one of the primary contributors to the strong double-digit revenue growth observed by the combined company. Management expects Synergy to contribute between $640–$650 million in fiscal 2017 which translates into low-single-digit sales growth.
STERIS has always been on track with its strategy of acquisitions for growth. In Jul 2016, the company bought Medisafe Holdings, which is a U.K.-based manufacturer of washer disinfector equipment and also markets related consumables and services. Per management, Medisafe’s products and services complement STERIS’ global healthcare offering by providing washer R&D and production in the U.K.
However, currency has been a major obstacle to STERIS' growth for quite some time. During first-quarter fiscal 2017, currency fluctuations affected STERIS’ revenues by 40 basis points. Additionally, the company’s lowered revenue guidance for fiscal 2017 was disappointing.
Moreover, the current macroeconomic turmoil in countries of the Middle East, owing to fluctuating oil prices, affected STERIS’ top line in the first quarter. Similar macroeconomic challenges were also witnessed across Latin America, Venezuela and Brazil.
Stocks to Consider
Some better-ranked stocks in the medical instrument space are IDEXX Laboratories, Inc. (IDXX - Free Report) , Masimo Corporation (MASI - Free Report) and CryoLife Inc. . All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>